We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Bayer AG | TG:BAYN | Tradegate | Ordinary Share |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.07 | 0.25% | 27.555 | 27.555 | 27.56 | 27.75 | 27.44 | 27.545 | 79,429 | 11:03:09 |
From Apr 2019 to Apr 2024
By Joshua Stein
Bayer AG on Thursday reported a fall in fourth-quarter profit and sales.
The German pharmaceutical and chemical conglomerate said net profit for the period fell by around 78% to 308 million euros ($374.9 million) from EUR1.41 billion a year earlier.
Earnings before interest, taxes, depreciation and amortization before special items were EUR2.39 billion, down from EUR2.48 billion.
Quarterly sales came in at EUR10.00 billion, down from EUR10.75 billion, but were higher than the third quarter, Bayer said.
Analysts expected sales to be EUR10.01 billion, according to a consensus provided by Vara Research.
Bayer proposed a dividend of EUR2.00 per share for 2020, in comparison to EUR2.80 the previous year.
Looking ahead, Bayer expects sales between around EUR42 billion and EUR43 billion for 2021, with an Ebitda before special items of EUR11.2 billion to EUR11.5 billion, both on currency-adjusted basis.
Write to Joshua Stein at joshua.stein@wsj.com
(END) Dow Jones Newswires
February 25, 2021 02:32 ET (07:32 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.
1 Year Bayer Chart |
1 Month Bayer Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
